Skip to content

Inpatient Penicillin Delabeling for Low-Risk Patients

Inpatient Penicillin Delabeling for Low-Risk Patients

Status
Enrolling by invitation
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06414694
Enrollment
25
Registered
2024-05-16
Start date
2023-09-01
Completion date
2025-09-30
Last updated
2024-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Allergy, Penicillin

Brief summary

This study seeks to enroll patients admitted to a children's hospital with identified penicillin allergy. A screening checklist is performed to identify patients with very low or low risk histories of penicillin allergy to offer direct oral challenges to the antibiotic class to de-label patient's with drug allergies.

Detailed description

This is a pilot study looking to utilize a novel criterion to identify low risk penicillin allergies for patients admitted to a children's hospital to evaluate safety and efficacy of direct oral challenges to patients with very low or low risk histories as identified in novel criterion.

Interventions

Direct oral challenge to penicillin at a goal dose of 45 mg/kg given in a 10%/90% dose

Sponsors

University of Tennessee
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* Patients \>2 years * Patients identified via EMR as having a penicillin, amoxicillin, amoxicillin/clavulanic acid allergy

Exclusion criteria

* Female patients aged \>8 years of age * Patients with hemodynamic instability * Patients identified with moderate or high risk histories per protocol * Patients currently taking oral antihistamines in 48 hours prior to direct challenge * Patients currently taking oral steroids in 48 hours prior to direct challenge * Patients currently receiving medications for nausea, shortness of breath,

Design outcomes

Primary

MeasureTime frameDescription
Direct Oral Challenge2 hoursPass or Failure of direct oral challenge

Secondary

MeasureTime frameDescription
Follow-up at 4848 hoursFollow-up phone call to assess adverse reaction by 48 hours. Data to be collected by screening questionnaire to assess for reactions such as fever, rash, manufacturer labeled adverse side effects.
Follow-up at 6 months6 monthsFollow-up phone call to assess subsequent tolerance or reaction of penicillin based antibiotic if prescribed in this time period. Data to be collected by screening questionnaire.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026